Combination Therapy With Nivolumab and PD-L1/IDO Peptide Vaccine to Patients With Metastatic Melanoma
Clinical trial NCT03047928 · COMPLETED
Trial details
- NCT number
- NCT03047928
- Sponsor
- Inge Marie Svane
- Status
- COMPLETED
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-02-22
- Primary completion
- 2022-12-31
- Enrollment
- 48
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.